Venture Capital

Latest Headlines

Latest Headlines

Biotech VCs wager $1.1B in Q1, plus: top 5 rounds

Venture investing in the biotech sector hit the $1.1 billion mark in the first quarter of the year--a surprisingly strong showing for what has generally been a quiet season in the U.S. industry.

Biotech upstart grabs $18M to study a new drug to protect pregnancies

A biotech startup with roots in Palo Alto, CA has raised $18 million in venture cash to open up a second mid-stage study of its lead therapy, looking to shape a reputation for itself in the lightly populated R&D world of reproductive medicine.

Column Group nears goal line for $250M biotech venture fund

The Column Group has been a busy venture player in the biotech world. And the VC plans to stay busy. In a recent filing at the FDA, the venture group revealed that it has raised close to $176 million out of a planned $250 million fund.

Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy

Parisian biotech AAVLife has come out of stealth with a Versant Ventures-led $12 million A round, looking to advance a gene-deleting therapy that promises to treat the rare and deadly Friedreich's ataxia.

VCs gamble $45M on PhII pain drug, new U.S. base for Spinifex

An Australian biotech company with a mid-stage pain drug is using a new $45 million venture round from a group that includes a pair of marquee international investors to put down U.S. roots in Stamford, CT, as it pushes ahead in the clinic. The Series C brings Spinifex Pharmaceuticals' total raise to $70 million, says CEO Tom McCarthy, with enough money committed to fund operations for the next three years.

Three IPO hopefuls look to squeeze out $144M as biotech gets bearish

After a record-setting first quarter put billions in the pockets of drug developers, second class of biotech upstarts is scrambling to cash out on Wall Street before an increasingly shaky market shuts the door on life sciences IPOs.

Cerulean stumbles with IPO as investors fret over biotech stocks

Adamas Pharmaceuticals had to price its IPO at the low end of the range today, then saw the stock price surge in early trading. But the lingering damage of a failed Phase IIb study could be seen when Cerulean stumbled onto the IPO stage after cutting its share price to a mere $7, well below the $11 to $13 range that had been hoped for.

Meet Spero, a biotech hopeful with Roche's blessing and a novel antibiotic

With seed funding from Atlas Venture and an early-stage partnership with Roche, startup Spero Therapeutics is striking out with a novel approach to drug-resistant bacteria amid an antibiotic sea change in the industry.

Low-profile Alios gets a roster of Big Pharma funds to back anti-RSV therapy

Even after out-licensing a pair of hepatitis C therapeutic candidates to Vertex, which was bidding on finding a contender as a new wave of transformational drugs approached the market, South San Francisco-based Alios BioPharma stubbornly maintained a very low profile.

Deerfield eyeing new biotech investments after launching $1.6B fund

Deerfield Management, one of the busiest institutional players in the biotech scene, has rounded up $1.6 billion to back a new wave of biopharma companies, a major niche for this big healthcare gambler.